The oncology field has seen significant changes in the last 5-8 years primarily in the launching of several new molecule entities (NME) that provide treatment options for patients in niche or sub-populations for some of the more widely recognised cancer tumour types.

This trend is expected to continue in the future as this commercial strategy of addressing these targeted population groups, such as patients expressing the PD-L1 biomarker within a larger disease population is a more attractive and successful commercial model for companies developing innovation in Oncology.

Being able to identify these relevant patient populations, defined by specific biomarkers and patient comorbidities, is critical to understand the addressable market for these breakthrough technologies.

In responding to this need, Black Swan Analysis has expanded its Epiomic™ Epidemiology series of Reports to cover six of the largest cancer types that are generating the most clinical development activity – Non-Hodgkin LymphomaCervical CancerProstate CancerMultiple MyelomaLeukaemia, and Hodgkin’s Lymphoma.

Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027Cervical Cancer Forecast in 22 Major Markets 2016-2026Prostate Cancer Forecast in 18 Major Markets 2016-2026
Read moreRead moreRead more
Multiple Myeloma Forecast in 18 Major Markets 2016-2026Leukaemia Forecast in 18 Major Markets 2017-2027Hodgkin’s Lymphoma Forecast in 17 Major Markets 2016-2026
Read moreRead moreRead more

Each report is generated utilising the most up to date clinical patient population data sources and robust modelling methodology, to forecast the future potential in each market. The structure of each report delivers:

  • Analyst insights about the disease or disorder
  • Top-line prevalence by individual market and gender
  • A breakdown of the prevalence or incidence population by gender in 5 year cohorts for each country across a ten year period
  • Relevant co-morbid or sub-population data

The geographic coverage for each report includes the core 12 Major Global Markets (USA, Germany, France, Italy, Spain, UK, Japan, Russia, China, Canada, India and Brazil) and additional 6-10 countries depending on the particular disease.

If you are operating within the Oncology space with existing products or potential opportunities in clinical development, it is important to ensure you have captured the relevant patient populations and the trends that can considerably impact these addressable populations over time.

Although we have highlighted the six most impactful cancer types in terms of clinical development activity, there is over 19 different Oncology disease reports available within our Epiomic Epidemiology Series of Reports.

Access to these reports will deliver a consistent picture of the eligible patient population across several major markets through our easy to understand reports.

All the reports can be purchased online via our website,, or alternatively you can contact the sales team at who can arrange a favourable volume discount if more than 1 report is purchased.